知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

310 条记录 (耗时 0.06 秒)

    METHOD FOR ANALYSIS OF AN RNA MOLECULE
    32.
    发明申请
    METHOD FOR ANALYSIS OF AN RNA MOLECULE 审中-公开

    公开(公告)号：US20190017100A1

    公开(公告)日：2019-01-17

    申请号：US15738641

    申请日：2016-07-01

    申请人： CureVac AG

    发明人： Aniela WOCHNER ,  Fabian Johannes EBER

    IPC分类号： C12Q1/6811 ,  C12Q1/6806 ,  C12Q1/6809 ,  C12N15/11

    摘要： The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule and/or of a population of RNA molecules. In one aspect, the invention concerns methods for analyzing RNA molecules having at least one cleavage site for at least one catalytic nucleic acid molecule. In particular, the invention concerns a method for determining a physical property of an RNA molecule by analyzing a 5′ terminal fragment, a 3′ terminal fragment and/or at least one optional central RNA fragment obtained by cleavage of the RNA molecule by at least one catalytic nucleic acid molecule. Moreover, the present invention provides novel uses of a catalytic nucleic acid molecule for analyzing RNA molecules. In particular, the invention relates to the use of a catalytic nucleic acid molecule in a method for analyzing RNA molecules, wherein the resulting 5′ terminal RNA fragment, the 3′ terminal RNA fragment and/or the at least one optional central RNA fragment are analyzed.

    NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION
    33.
    发明申请
    NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION 审中-公开

    公开(公告)号：US20190008954A1

    公开(公告)日：2019-01-10

    申请号：US16004871

    申请日：2018-06-11

    申请人： CureVac AG

    发明人： Patrick BAUMHOF

    IPC分类号： A61K39/39 ,  A61K47/64 ,  A61K47/59 ,  A61K47/54 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00

    摘要： The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.

    Respiratory syncytial virus (RSV) vaccine
    34.
    发明授权
    Respiratory syncytial virus (RSV) vaccine 有权

    公开(公告)号：US10150797B2

    公开(公告)日：2018-12-11

    申请号：US15488815

    申请日：2017-04-17

    申请人： CureVac AG

    发明人： Thomas Kramps ,  Margit Schnee ,  Daniel Voss ,  Benjamin Petsch

    IPC分类号： A61K39/215 ,  C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C07K16/10 ,  C12N7/00 ,  A61K39/00 ,  A61K48/00

    摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

    OPTIMIZED NUCLEIC ACID MOLECULES
    35.
    发明申请
    OPTIMIZED NUCLEIC ACID MOLECULES 审中-公开

    公开(公告)号：US20180312545A1

    公开(公告)日：2018-11-01

    申请号：US15774423

    申请日：2016-11-09

    申请人： CureVac AG

    发明人： Patrick BAUMHOF ,  Susanne RAUCH ,  Aleksandra KOWALCZYK ,  Johannes LUTZ ,  Edith JASNY ,  Benjamin PETSCH ,  Andreas THESS ,  Thomas SCHLAKE ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Sandra LAZZARO ,  Fatma DÖNER ,  Wolfgang GROSSE

    IPC分类号： C07K14/005 ,  C07K14/205 ,  A61K39/145

    CPC分类号： C12N15/00 ,  A61K39/12 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

    摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

    LYOPHILIZATION OF RNA
    38.
    发明申请
    LYOPHILIZATION OF RNA 审中-公开

    公开(公告)号：US20180243219A1

    公开(公告)日：2018-08-30

    申请号：US15566980

    申请日：2016-04-15

    申请人： CureVac AG

    发明人： Thomas KETTERER ,  Thorsten MUTZKE ,  Michael WIGGENHORN ,  Frank SCHAUBHUT ,  Florian VON DER MÜLBE

    IPC分类号： A61K9/19 ,  A61K31/7105 ,  A61K47/54 ,  A61K47/64

    摘要： The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.